Get the Stockscreener App
11.05
0.18%
-0.077
Theravance Biopharma Inc stock is traded at $11.05, with a volume of 26,952.
It is down -0.18% in the last 24 hours and up +5.01% over the past month.
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
See More
Previous Close:
$11.13
Open:
$11.09
24h Volume:
26,952
Relative Volume:
0.10
Market Cap:
$552.76M
Revenue:
$62.02M
Net Income/Loss:
$-45.65M
P/E Ratio:
-12.01
EPS:
-0.92
Net Cash Flow:
$-9.60M
1W Performance:
-1.24%
1M Performance:
+5.01%
6M Performance:
+6.11%
1Y Performance:
+8.81%
1-Day Range:
$11.05
$11.18
1-Week Range:
$11.08
$11.41
52-Week Range:
$7.44
$11.88
Theravance Biopharma Inc Stock (TBPH) Company Profile
Name
Theravance Biopharma Inc
Sector
Industry
Phone
650-808-6000
Address
UGLAND HOUSE, SOUTH CHURCH STREET, GEORGE TOWN, GRAND CAYMAN
Compare TBPH with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TBPH
Theravance Biopharma Inc
|
11.05 | 565.02M | 62.02M | -45.65M | -9.60M | -0.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.04 | 122.48B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.55 | 61.80B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.43 | 42.46B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.37 | 35.22B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.82 | 31.91B | 3.81B | -644.79M | -669.77M | -6.24 |
Theravance Biopharma Inc Stock (TBPH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-06-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Apr-12-24 | Initiated | BTIG Research | Buy |
| Jan-08-24 | Downgrade | Evercore ISI | Outperform → In-line |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Nov-05-21 | Upgrade | JP Morgan | Underweight → Neutral |
| Sep-15-21 | Downgrade | JP Morgan | Overweight → Underweight |
| Aug-25-21 | Downgrade | Morgan Stanley | Overweight → Underweight |
| Aug-24-21 | Downgrade | Cowen | Outperform → Market Perform |
| Oct-14-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jul-07-20 | Initiated | JP Morgan | Overweight |
| Jun-15-20 | Initiated | Morgan Stanley | Equal-Weight |
| May-13-20 | Initiated | Cowen | Outperform |
| Jan-08-20 | Reiterated | H.C. Wainwright | Buy |
| Nov-06-19 | Upgrade | Robert W. Baird | Underperform → Neutral |
| Oct-29-19 | Initiated | H.C. Wainwright | Buy |
| Mar-29-18 | Resumed | Piper Jaffray | Overweight |
| Aug-17-17 | Initiated | Evercore ISI | Outperform |
| Jun-16-17 | Initiated | Cantor Fitzgerald | Overweight |
| May-11-17 | Reiterated | Needham | Buy |
| Dec-21-16 | Initiated | Needham | Buy |
| Nov-03-16 | Initiated | Piper Jaffray | Overweight |
| Oct-12-16 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Aug-03-16 | Downgrade | BofA/Merrill | Neutral → Underperform |
| Jun-20-16 | Initiated | Guggenheim | Buy |
| Jun-20-16 | Reiterated | Leerink Partners | Outperform |
| May-12-16 | Initiated | Leerink Partners | Outperform |
| May-05-16 | Downgrade | BofA/Merrill | Buy → Neutral |
| Feb-03-15 | Upgrade | Robert W. Baird | Underperform → Neutral |
View All
Theravance Biopharma Inc Stock (TBPH) Latest News
Why Theravance Biopharma Inc. stock attracts strong analyst attentionWealth Accumulation Stock List - Newser
Is Theravance Biopharma Inc. a good long term investmentRecord-breaking gains - PrintWeekIndia
What analysts say about Theravance Biopharma Inc. stockUnbelievable profit margins - PrintWeekIndia
Theravance Biopharma Inc. Stock Analysis and ForecastExceptional trading results - Autocar Professional
Theravance Biopharma to Participate in an Upcoming Investor Conference - Citizen Tribune
What drives Theravance Biopharma Inc. stock priceConsistent triple-digit returns - jammulinksnews.com
How Theravance Biopharma Inc. stock performs during market volatilitySecure Your Capital Strategy - Newser
Zacks Industry Outlook Highlights Catalyst Pharmaceuticals, Zevra Therapeutics, Theravance Biopharma, Aldeyra Therapeutics and Larimar Therapeutics - The Globe and Mail
Theravance Biopharma SVP Farnum sells $113,869 in stock By Investing.com - Investing.com Nigeria
Theravance Biopharma SVP Farnum sells $113,869 in stock - Investing.com
5 Small Drug Stocks to Buy Amid Trump's New Tariff Threats - The Globe and Mail
What makes Theravance Biopharma Inc. stock price move sharplyStrategic High Profit Opportunities - Newser
Viatris Gains China Approval for COPD Drug Yupelri, Triggers $7.5M Payment to Theravance BioPharma - Insider Monkey
Brokerages Set Theravance Biopharma, Inc. (NASDAQ:TBPH) Target Price at $16.60 - Defense World
Theravance Biopharma SVP Sells 7,000 Shares for $78,000 on July 14, 2025. - AInvest
Theravance higher as China approves Viatris-partnered COPD therapy - MSN
Theravance Biopharma (NASDAQ:TBPH) Downgraded to “Hold” Rating by Wall Street Zen - Defense World
Theravance Biopharma, Inc.(NasdaqGM:TBPH) dropped from Russell 2000 Defensive Index - MarketScreener
Theravance Biopharma, Inc.(NasdaqGM: TBPH) added to Russell Microcap Growth Index - MarketScreener
Theravance Biopharma (NASDAQ:TBPH) Given New $25.00 Price Target at BTIG Research - Defense World
TBPH Stock Price Target Increased Following Milestone Payment | TBPH Stock News - GuruFocus
JonesTrading Maintains Theravance Biopharma(TBPH.US) With Buy Rating, Maintains Target Price $24 - 富途牛牛
Theravance Biopharma price target raised to $25 by BTIG on China approval - Investing.com
Is Theravance Biopharma, Inc. technically bullish or bearish? - MarketsMojo
Theravance Biopharma (NASDAQ:TBPH) Now Covered by Jones Trading - Defense World
Theravance Biopharma (NASDAQ:TBPH) Stock Rating Upgraded by Jones Trading - Defense World
Theravance Biopharma Inc Stock (TBPH) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.74%
0.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):